Polaryx Therapeutics IPO: offering terms from its S-1
Polaryx Therapeutics listed on Nasdaq as PLYX on 2 Feb 2026 in a direct listing.
Headlines
- Net loss, 2024
- $30M
- Price range
- Not set yet
Polaryx Therapeutics IPO terms
From the final prospectus (424B4).
- Exchange
- The Nasdaq Capital Market
- Ticker
- PLYX
- IPO price
- Direct listing
- Registered
- $483M, the amount the filing fee is paid on
- First filed
- 21 Nov 2025
Polaryx Therapeutics revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2024 | - | -$4M | -$30M |
| First nine months of 2025 | - | -$7M | -$7M |
Polaryx Therapeutics share structure and company facts
- Employees
- 11
- Headquarters
- Paramus, New Jersey
Polaryx Therapeutics' IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Polaryx Therapeutics' newest prospectus (S-1/A filed 27 Jan 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.